Title: MilliporeSigma Small Molecule Innovations
Abstract:
The Madison site of MilliporeSigma is home to an R&D team which was founded to develop innovative solutions in the antibody drug conjugates (ADC) space. ADCs utilize a combination of antibodies and small molecule linkers and highly potent payloads. Our team leverages robust synthetic chemistry to transfer scalable manufacturing processes of these difficult to handle payloads in order to maximize impact for our customers and patients. Presented within are highlights from some of our exatecan and monomethyl auristatin E (MMAE) projects.
Bio:
Andrew Chen, Ph.D., is a chemist in the small molecules R&D group in MilliporeSigma’s Madison site, where he develops scalable processes for highly potent, complex small molecules. He earned his Ph.D. with Prof. David Nagib at the Ohio State University where his work focused on the intersection of utilizing radicals to develop C-H functionalization synthetic methods and computational modeling.
Host: Prof. Shannon Stahl